Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2024 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| Texto Completo: | http://hdl.handle.net/10362/168691 |
| Resumo: | Publisher Copyright: © 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. |
| id |
RCAP_251102e12cf101ae703fcf436e47ae66 |
|---|---|
| oai_identifier_str |
oai:run.unl.pt:10362/168691 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository_id_str |
7160 |
| spelling |
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fractionThe FINEARTS-HF trialClinical trialsHeart failure with mildly reduced or preserved ejection fractionMineralocorticoid receptor antagonistsCardiology and Cardiovascular MedicinePublisher Copyright: © 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.Aims: To describe the baseline characteristics of participants in the FINEARTS-HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS-HF trial is comparing the effects of the non-steroidal mineralocorticoid receptor antagonist finerenone with placebo in reducing cardiovascular death and total worsening HF events in patients with HFmrEF/HFpEF. Methods and results: Patients with symptomatic HF, left ventricular ejection fraction (LVEF) ≥40%, estimated glomerular filtration rate ≥ 25 ml/min/1.73 m2, elevated natriuretic peptide levels and evidence of structural heart disease were enrolled and randomized to finerenone titrated to a maximum of 40 mg once daily or matching placebo. We validly randomized 6001 patients to finerenone or placebo (mean age 72 ± 10 years, 46% women). The majority were New York Heart Association functional class II (69%). The baseline mean LVEF was 53 ± 8% (range 34–84%); 36% of participants had a LVEF <50% and 64% had a LVEF ≥50%. The median N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 1041 (interquartile range 449–1946) pg/ml. A total of 1219 (20%) patients were enrolled during or within 7 days of a worsening HF event, and 3247 (54%) patients were enrolled within 3 months of a worsening HF event. Compared with prior large-scale HFmrEF/HFpEF trials, FINEARTS-HF participants were more likely to have recent (within 6 months) HF hospitalization and greater symptoms and functional limitations. Further, concomitant medications included a larger percentage of sodium–glucose cotransporter 2 inhibitors and angiotensin receptor–neprilysin inhibitors than previous trials. Conclusions: FINEARTS-HF has enrolled a broad range of high-risk patients with HFmrEF and HFpEF. The trial will determine the safety and efficacy of finerenone in this population.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNSolomon, Scott D.Ostrominski, John W.Vaduganathan, MuthiahClaggett, BrianJhund, Pardeep S.Desai, Akshay S.Lam, Carolyn S.P.Pitt, BertramSenni, MicheleShah, Sanjiv J.Voors, Adriaan A.Zannad, FaiezAbidin, Imran ZainalAlcocer-Gamba, Marco AntonioAtherton, John J.Bauersachs, JohannMa, Chang ShengChiang, Chern EnChioncel, OvidiuChopra, VijayComin-Colet, JosepFilippatos, GerasimosFonseca, CândidaGajos, GrzegorzGoland, SorelGoncalvesová, EvaKang, Seok MinKatova, TzvetanaKosiborod, Mikhail N.Latkovskis, GustavsLee, Alex Pui WaiLinssen, Gerard C.M.Llamas-Esperón, GuillermoMareev, VyacheslavMartinez, Felipe A.Melenovský, VojtěchMerkely, BélaNodari, SavinaPetrie, Mark C.Saldarriaga, Clara InésSaraiva, Jose Francisco KerrSato, NaokiSchou, MortenSharma, KavitaTroughton, RichardUdell, Jacob A.Ukkonen, HeikkiVardeny, OrlyVerma, Subodhvon Lewinski, DirkVoronkov, Leonid G.Yilmaz, Mehmet BirhanZieroth, ShelleyLay-Flurrie, Jamesvan Gameren, IlseAmarante, FlavianaViswanathan, PrabhakarMcMurray, John J.V.2024-06-18T01:27:18Z20242024-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/168691eng1388-9842PURE: 92618380https://doi.org/10.1002/ejhf.3266info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-06-24T01:35:50Zoai:run.unl.pt:10362/168691Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-06-24T01:35:50Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
| dc.title.none.fl_str_mv |
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction The FINEARTS-HF trial |
| title |
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction |
| spellingShingle |
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction Solomon, Scott D. Clinical trials Heart failure with mildly reduced or preserved ejection fraction Mineralocorticoid receptor antagonists Cardiology and Cardiovascular Medicine |
| title_short |
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction |
| title_full |
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction |
| title_fullStr |
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction |
| title_full_unstemmed |
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction |
| title_sort |
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction |
| author |
Solomon, Scott D. |
| author_facet |
Solomon, Scott D. Ostrominski, John W. Vaduganathan, Muthiah Claggett, Brian Jhund, Pardeep S. Desai, Akshay S. Lam, Carolyn S.P. Pitt, Bertram Senni, Michele Shah, Sanjiv J. Voors, Adriaan A. Zannad, Faiez Abidin, Imran Zainal Alcocer-Gamba, Marco Antonio Atherton, John J. Bauersachs, Johann Ma, Chang Sheng Chiang, Chern En Chioncel, Ovidiu Chopra, Vijay Comin-Colet, Josep Filippatos, Gerasimos Fonseca, Cândida Gajos, Grzegorz Goland, Sorel Goncalvesová, Eva Kang, Seok Min Katova, Tzvetana Kosiborod, Mikhail N. Latkovskis, Gustavs Lee, Alex Pui Wai Linssen, Gerard C.M. Llamas-Esperón, Guillermo Mareev, Vyacheslav Martinez, Felipe A. Melenovský, Vojtěch Merkely, Béla Nodari, Savina Petrie, Mark C. Saldarriaga, Clara Inés Saraiva, Jose Francisco Kerr Sato, Naoki Schou, Morten Sharma, Kavita Troughton, Richard Udell, Jacob A. Ukkonen, Heikki Vardeny, Orly Verma, Subodh von Lewinski, Dirk Voronkov, Leonid G. Yilmaz, Mehmet Birhan Zieroth, Shelley Lay-Flurrie, James van Gameren, Ilse Amarante, Flaviana Viswanathan, Prabhakar McMurray, John J.V. |
| author_role |
author |
| author2 |
Ostrominski, John W. Vaduganathan, Muthiah Claggett, Brian Jhund, Pardeep S. Desai, Akshay S. Lam, Carolyn S.P. Pitt, Bertram Senni, Michele Shah, Sanjiv J. Voors, Adriaan A. Zannad, Faiez Abidin, Imran Zainal Alcocer-Gamba, Marco Antonio Atherton, John J. Bauersachs, Johann Ma, Chang Sheng Chiang, Chern En Chioncel, Ovidiu Chopra, Vijay Comin-Colet, Josep Filippatos, Gerasimos Fonseca, Cândida Gajos, Grzegorz Goland, Sorel Goncalvesová, Eva Kang, Seok Min Katova, Tzvetana Kosiborod, Mikhail N. Latkovskis, Gustavs Lee, Alex Pui Wai Linssen, Gerard C.M. Llamas-Esperón, Guillermo Mareev, Vyacheslav Martinez, Felipe A. Melenovský, Vojtěch Merkely, Béla Nodari, Savina Petrie, Mark C. Saldarriaga, Clara Inés Saraiva, Jose Francisco Kerr Sato, Naoki Schou, Morten Sharma, Kavita Troughton, Richard Udell, Jacob A. Ukkonen, Heikki Vardeny, Orly Verma, Subodh von Lewinski, Dirk Voronkov, Leonid G. Yilmaz, Mehmet Birhan Zieroth, Shelley Lay-Flurrie, James van Gameren, Ilse Amarante, Flaviana Viswanathan, Prabhakar McMurray, John J.V. |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) RUN |
| dc.contributor.author.fl_str_mv |
Solomon, Scott D. Ostrominski, John W. Vaduganathan, Muthiah Claggett, Brian Jhund, Pardeep S. Desai, Akshay S. Lam, Carolyn S.P. Pitt, Bertram Senni, Michele Shah, Sanjiv J. Voors, Adriaan A. Zannad, Faiez Abidin, Imran Zainal Alcocer-Gamba, Marco Antonio Atherton, John J. Bauersachs, Johann Ma, Chang Sheng Chiang, Chern En Chioncel, Ovidiu Chopra, Vijay Comin-Colet, Josep Filippatos, Gerasimos Fonseca, Cândida Gajos, Grzegorz Goland, Sorel Goncalvesová, Eva Kang, Seok Min Katova, Tzvetana Kosiborod, Mikhail N. Latkovskis, Gustavs Lee, Alex Pui Wai Linssen, Gerard C.M. Llamas-Esperón, Guillermo Mareev, Vyacheslav Martinez, Felipe A. Melenovský, Vojtěch Merkely, Béla Nodari, Savina Petrie, Mark C. Saldarriaga, Clara Inés Saraiva, Jose Francisco Kerr Sato, Naoki Schou, Morten Sharma, Kavita Troughton, Richard Udell, Jacob A. Ukkonen, Heikki Vardeny, Orly Verma, Subodh von Lewinski, Dirk Voronkov, Leonid G. Yilmaz, Mehmet Birhan Zieroth, Shelley Lay-Flurrie, James van Gameren, Ilse Amarante, Flaviana Viswanathan, Prabhakar McMurray, John J.V. |
| dc.subject.por.fl_str_mv |
Clinical trials Heart failure with mildly reduced or preserved ejection fraction Mineralocorticoid receptor antagonists Cardiology and Cardiovascular Medicine |
| topic |
Clinical trials Heart failure with mildly reduced or preserved ejection fraction Mineralocorticoid receptor antagonists Cardiology and Cardiovascular Medicine |
| description |
Publisher Copyright: © 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024-06-18T01:27:18Z 2024 2024-01-01T00:00:00Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/168691 |
| url |
http://hdl.handle.net/10362/168691 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
1388-9842 PURE: 92618380 https://doi.org/10.1002/ejhf.3266 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
| instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| repository.mail.fl_str_mv |
mluisa.alvim@gmail.com |
| _version_ |
1817546127117910016 |
